Alnylam Gets VIP Status as the FDA Slaps Breakthrough Tag on Patisiran Post author:Sam Post published:November 19, 2017 Post category:BioPharma The company is weeks away from completing its rolling NDA for Patisiran. Source: BioSpace You Might Also Like PharmaCyte Presents Options for Phase II Pancreatic Cancer Trial February 27, 2018 Otsuka Pharma Believes in Akebia, Commits Another $865 Million to Expand Anemia Deal April 25, 2017 Celyad Grants To Novartis AG A Non-Exclusive License For Its Allogeneic TCR-Deficient CAR-T Cells Patents May 1, 2017
Celyad Grants To Novartis AG A Non-Exclusive License For Its Allogeneic TCR-Deficient CAR-T Cells Patents May 1, 2017
